Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial

• Published in: Journal of clinical oncology Vol. 42; no. 10; pp. JCO2300458 - 1145
• Main Authors: Moreno, Lucas, Weston, Rebekah, Owens, Cormac, Valteau-Couanet, Dominique, Gambart, Marion, Castel, Victoria, Zwaan, C Michel, Nysom, Karsten, Gerber, Nicolas, Castellano, Aurora, Laureys, Genevieve, Ladenstein, Ruth, Rössler, Jochen, Makin, Guy, Murphy, Dermot, Morland, Bruce, Vaidya, Sucheta, Thebaud, Estelle, van Eijkelenburg, Natasha, Tweddle, Deborah A, Barone, Giuseppe, Tandonnet, Julie, Corradini, Nadege, Chastagner, Pascal, Paillard, Catherine, Bautista, Francisco J, Gallego Melcon, Soledad, De Wilde, Bram, Marshall, Lynley, Gray, Juliet, Burchill, Susan A, Schleiermacher, Gudrun, Chesler, Louis, Peet, Andrew, Leach, Martin O, McHugh, Kieran, Hayes, Roisin, Jerome, Neil, Caron, Hubert, Laidler, Jennifer, Fenwick, Nicola, Holt, Grace, Moroz, Veronica, Kearns, Pamela, Gates, Simon, Pearson, Andrew D J, Wheatley, Keith
• Format: Journal Article
• Language: English
• Published: United States 01.04.2024

Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens and the addition of the antiangiogenic agent bevacizumab (B). Patients age 1-21 years with RR-HRN...